Crinetics Pharmaceuticals, Inc.
CRNX
$30.93
$0.842.79%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 158.40% | -43.59% | -- | -- | -59.62% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 158.40% | -43.59% | -- | -- | -59.62% |
| Cost of Revenue | 13.99% | 42.93% | 46.04% | 41.21% | -71.72% |
| Gross Profit | -8.80% | -43.98% | -46.04% | -42.33% | 72.03% |
| SG&A Expenses | 100.67% | 70.57% | 65.00% | 67.22% | 86.15% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 56.46% | 50.69% | 51.21% | 48.00% | 54.09% |
| Operating Income | -55.96% | -51.51% | -51.21% | -48.87% | -56.21% |
| Income Before Tax | -56.15% | -44.59% | -34.11% | -33.71% | -45.27% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -56.15% | -44.59% | -34.11% | -33.71% | -45.27% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -56.15% | -44.59% | -34.11% | -33.71% | -45.27% |
| EBIT | -55.96% | -51.51% | -51.21% | -48.87% | -56.21% |
| EBITDA | -56.23% | -51.23% | -50.58% | -48.25% | -55.61% |
| EPS Basic | -31.54% | -12.26% | 1.58% | 5.15% | 0.21% |
| Normalized Basic EPS | -31.55% | -12.27% | 1.59% | 5.17% | 0.20% |
| EPS Diluted | -31.54% | -12.26% | 1.58% | 5.15% | 0.21% |
| Normalized Diluted EPS | -31.55% | -12.27% | 1.59% | 5.17% | 0.20% |
| Average Basic Shares Outstanding | 18.71% | 28.79% | 36.26% | 40.99% | 45.57% |
| Average Diluted Shares Outstanding | 18.71% | 28.79% | 36.26% | 40.99% | 45.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |